Explore GnRH (Triptorelin) dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
Triptorelin is a long-acting GnRH agonist and an FDA-approved drug (Trelstar) also sold as research-grade material; unlike gonadorelin, continuous dosing suppresses LH/FSH. It ships as a lyophilized powder you reconstitute before use, so vendor quality comes down to what the certificate of analysis (COA) shows.
Triptorelin's D-amino-acid substitution gives it a much longer plasma half-life and ~100× the receptor affinity of native GnRH. After an initial 1–2 week "flare" of LH/FSH release, sustained receptor occupancy produces GnRH-receptor desensitisation, internalisation, and uncoupling from downstream signalling — collapsing LH/FSH secretion and producing castrate testosterone levels in men or postmenopausal oestradiol levels in women within 3–4 weeks.[2][3]
Triptorelin is established standard-of-care in androgen-deprivation therapy for advanced prostate cancer (often combined with an anti-androgen in the first month to block the flare),[2] in suppression of central precocious puberty,[4] and in endometriosis and uterine-fibroid medical management.[5] In research-peptide community use, single-dose triptorelin (100 µg) is occasionally used as an "HPG-axis test" or for short-term flare-induced LH release, distinct from approved depot-dosing.
FDA-approved as Trelstar (depot formulation for advanced prostate cancer). Internationally approved as Decapeptyl/Diphereline for additional indications. Use as a single-injection HPG-axis stimulator outside approved depot-dosing is off-label.
GnRH (Triptorelin) has a reported half-life of ~3 hours (immediate-release). The pharmacokinetic reference models an interval of once daily (or single trigger dose); this is not a measured community cadence or a dosing recommendation. Short plasma half-life means the immediate-release form clears within a day and does not accumulate; it works as a discrete GnRH pulse rather than a steady level (depot formulations behave very differently). Pharmacokinetic source: FDA label (Trelstar) and triptorelin clinical PK literature. It is catalogued under Testosterone Peptides on WPA.
1 GnRH (Triptorelin) reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.